# approved (podcasts) — RSS Amplifier Recent posts from the 3 feeds in the RSS Amplifier directory that cover approved. Page: Feed: --- ## [Iberdomide](https://soundcloud.com/user-650920398/iberdomide) _2026-08-20 · OncoPharm_ CELMoDs are here, but are they here to stay? CELMoD/IMiD review article: https://doi.org/10.1080/17474086.2024.2382897 Download the Oncology Learning Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm [Listen](https://feeds.soundcloud.com/stream/2385251205-user-650920398-iberdomide.mp3) ## [Navigating the New mRNA Flu Shot: A Discussion With Dr William Schaffner](https://mprweeklydose.libsyn.com/navigating-the-new-mrna-flu-shot-a-discussion-with-dr-william-schaffner) _2026-08-17 · MPR Weekly Dose_ In a special episode of the MPR Weekly Dose podcast, Dr William Schaffner — professor of preventive medicine and infectious diseases at Vanderbilt University School of Medicine and former CDC Epidemic Intelligence Service officer — discusses the clinical rollout of mFlusiva, the newly-approved mRNA-based influenza vaccine. Dr Schaffner breaks down how this modern platform differs from traditional… [Listen](https://traffic.libsyn.com/secure/mprweeklydose/Navigating_the_New_mRNA_Flu_Shot_-_A_Discussion_With_Dr_William_Schaffner.mp3?dest-id=1953617) ## [Kidney Cancer in a Nutshell](https://soundcloud.com/user-650920398/kidney-cancer-in-a-nutshell) _2026-08-13 · OncoPharm_ Overview of renal cell carcinoma Learning Oncology Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm [Listen](https://feeds.soundcloud.com/stream/2381254023-user-650920398-kidney-cancer-in-a-nutshell.mp3) ## [MPR Weekly Dose Podcast #283 — mRNA Influenza Vaccine; Pluvicto for PSMA+ mHSPC; Mucinex 12HR Approved; Narcolepsy Tx Approved; Peanut Allergy Treatment Fast Tracked](https://mprweeklydose.libsyn.com/mpr-weekly-dose-podcast-283-mrna-influenza-vaccine-pluvicto-for-psma-mhspc-mucinex-12hr-approved-narcolepsy-tx-approved-peanut-allergy-treatment-fast-tracked) _2026-08-07 · MPR Weekly Dose_ Moderna's mRNA influenza vaccine gains FDA approval; approvals for prostate cancer, narcolepsy type 1 and Mucinex 12HR; and peanut allergy treatment gains Fast Track status. [Listen](https://traffic.libsyn.com/secure/mprweeklydose/MPR_Weekly_Dose_Podcast_283__mRNA_Influenza_Vaccine_Pluvicto_for_PSMA_mHSPC_Mucinex_12HR_Approved_Narcolepsy_Tx_Approved_Peanut_Allergy_Treatment_Fast_Tracked_mixdown.mp3?dest-id=1953617) ## [Small Cell Lung Cancer and CINV Updates](https://soundcloud.com/user-650920398/small-cell-lung-cancer-and) _2026-08-06 · OncoPharm_ This week's episode covers some updates in small cell lung cancer, chemotherapy-induced nausea/vomiting (CINV), SC administration of isatuximab, and Lu-177 vipivotide tetraxetan. Download the Oncology Learning Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm [Listen](https://feeds.soundcloud.com/stream/2376827312-user-650920398-small-cell-lung-cancer-and.mp3) ## [MPR Weekly Dose Podcast #282 — OTC Acetaminophen/Naproxen; Novel ADHD Tx; COVID-19 PEP; Contraceptive Patch; Furosemide Autoinjector for Edema](https://mprweeklydose.libsyn.com/mpr-weekly-dose-podcast-282-otc-acetaminophennaproxen-novel-adhd-tx-covid-19-pep-contraceptive-patch-furosemide-autoinjector-for-edema) _2026-07-31 · MPR Weekly Dose_ An over-the-counter acetaminophen/naproxen sodium fixed-dose tablet gains approval; Simtriyo approved for ADHD; Xocova approved for COVID-19 postexposure prophylaxis; A new contraceptive patch is approved; and Furoscix ReadyFlow approval is expanded to treat edema in CHF, CKD. [Listen](https://traffic.libsyn.com/secure/mprweeklydose/MPR_Weekly_Dose_Podcast_282__OTC_Acetaminophen-Naproxen_Novel_ADHD_Tx_COVID-19_PEP_Contraceptive_Patch_Furosemide_Autoinjector_for_Edema_mixdown.mp3?dest-id=1953617) ## [Zidesamtinib & PPIs in Pacific](https://soundcloud.com/user-650920398/zidesamtinib-ppis-in-pacific) _2026-07-30 · OncoPharm_ A new drug is approved for ROS1 NSCLC after a prior TKI (with some data in patients after 2 TKIs). Zidesamtinib...easy for you to say. Also, a post hoc analysis of PACIFIC provides some of the best evidence yet of the detrimental effect (?) of PPI use prior to ICI use. Download the Oncology Learning Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm [Listen](https://feeds.soundcloud.com/stream/2370746021-user-650920398-zidesamtinib-ppis-in-pacific.mp3) ## [MPR Weekly Dose Podcast #281 — Kalshi Start Clinical Trial Predictions; Positive Results for Retatrutide; Jideytro Approved; Smart Toilet Launches; Daraxonrasib NDA Accepted](https://mprweeklydose.libsyn.com/mpr-weekly-dose-podcast-281-kalshi-start-clinical-trial-predictions-positive-results-for-retatrutide-jideytro-approved-smart-toilet-launches-daraxonrasib-nda-accepted) _2026-07-24 · MPR Weekly Dose_ Kalshi start clinical trials, FDA approvals prediction market; positive results shared for triple hormone therapy retatrutide; Jideytro gains approval in advanced or metastatic ROS1-positive NSCLC; a smart toilet seat hits the market to measure your vitals; and the FDA accepts an application for pretreated metastatic pancreatic cancer treatment, daraxonrasib. [Listen](https://traffic.libsyn.com/secure/mprweeklydose/MPR_Weekly_Dose_Podcast_281__Kalshi_Start_Clinical_Trial_Predictions_Positive_Results_for_Retatrutide_Jideytro_Approved_Smart_Toilet_Launches_Daraxonrasib_NDA_Accepted_mixdown.mp3?dest-id=1953617) ## [Gedatolisib et al](https://soundcloud.com/user-650920398/gedatolisib-et-al) _2026-07-23 · OncoPharm_ This week's pod covers some brief updates comparing the timelines of the FDA approvals for daraxonrasib vs. enfortuamb vedodin + pembrolizumab, before devoting the rest of the time to the new approval of gedatolisib, a PIK3CA inhibitor, with fulvestrant and maybe palbociclib if you feel like it for metastatic breast cancer in the 2nd line. Oh, in patients WITHOUT PIK3CA mutations. Download the… [Listen](https://feeds.soundcloud.com/stream/2366762669-user-650920398-gedatolisib-et-al.mp3) ## [MPR Weekly Dose Podcast #280 — Cyclospora Outbreak Latest; Hypercholesterolemia Tx Approved; New Lecanemab SC Regimen; Oral Sleep Apnea Tx; Revtorpyk Approved for Breast Cancer](https://mprweeklydose.libsyn.com/mpr-weekly-dose-podcast-280-cyclospora-outbreak-latest-hypercholesterolemia-tx-approved-new-lecanemab-sc-regimen-oral-sleep-apnea-tx-revtorpyk-approved-for-breast-cancer) _2026-07-17 · MPR Weekly Dose_ The latest on the multistate cyclospora outbreak; Lipfendra approved to reduce low-density lipoprotein cholesterol in adults with hypercholesterolemia; subcutaneous starting dose regimen approved for Leqembi; NDA accepted for oral sleep apnea treatment; and Revtorpyk combination approved for advanced breast cancer. [Listen](https://traffic.libsyn.com/secure/mprweeklydose/MPR_Weekly_Dose_Podcast_280__Cyclospora_Outbreak_Latest_Hypercholesterolemia_Tx_Approved_New_Lecanemab_SC_Regimen_Oral_Sleep_Apnea_Tx_Revtorpyk_Approved_for_Breast_Cancer_mixdown.mp3?dest-id=1953617) ## [Ship software peacefully (Sponsored)](https://crawlproof.com/a/1IQeiFWtt4Ld) _2026-07-17 · **Sponsored**_ Deploy apps from your repo with auto-config, instant previews, scaling, and monitoring. ## [Endurance Part 2](https://soundcloud.com/user-650920398/endurance-part-2) _2026-07-16 · OncoPharm_ Did lenalidomide maintenance in multiple myeloma just get limited to 2 years? Endurance Trial, Part 2: https://www.nejm.org/doi/full/10.1056/NEJMoa2600157 Learning Oncology Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm [Listen](https://feeds.soundcloud.com/stream/2362244609-user-650920398-endurance-part-2.mp3) ## [MPR Weekly Dose Podcast #279 — Trutakna Approved; Xtoro and Amerithroid Now Available; Casgevy Approval Expanded; Lupus Tx Granted Breakthrough Designation](https://mprweeklydose.libsyn.com/mpr-weekly-dose-podcast-279-trutakna-approved-xtoro-and-amerithroid-now-available-casgevy-approval-expanded-lupus-tx-granted-breakthrough-designation) _2026-07-10 · MPR Weekly Dose_ A new treatment is approved to reduce proteinuria in adults with primary immunoglobulin A nephropahty; a swimmer's ear treatment and the thyroid hormone replacement therapy Amerithroid are now available; Casgevy approval expanded include pediatrics; and a lupus treatment is granted breakthrough status. [Listen](https://traffic.libsyn.com/secure/mprweeklydose/MPR_Weekly_Dose_Podcast_279__Trutakna_Approved_Xtoro_and_Amerithroid_Now_Available_Casgevy_Approved_for_Younger_Patients_Lupus_Tx_Granted_Breakthrough_Designation__mixdown.mp3?dest-id=1953617) ## [A Decade of CAR-T, Ocra-T, & POLARGO](https://soundcloud.com/user-650920398/a-decade-of-car-t-ocra-t) _2026-07-09 · OncoPharm_ We are a decade into the CAR-T era, and what to long term outcomes look like with tisagenlecleucel in B-cell lymphomas? Orca-T is approved, an allogenic cocktail of stem & progenitor cells, Tregs, and then conventional T-cells. Neato. Polar-Go! or PolARGo? And the concept of T-cell "stemless" is intriguing with possibilities: DOI: 10.1056/NEJMcibr2601002 Learning Oncology… [Listen](https://feeds.soundcloud.com/stream/2356422722-user-650920398-a-decade-of-car-t-ocra-t.mp3) ## [Breast Cancer Updates and T-Cell Stemness](https://soundcloud.com/user-650920398/breast-cancer-updates-and-t) _2026-06-25 · OncoPharm_ This week we discuss a new approval for pabociclib in HER2-positive disease based on the PATINA trial as well as the use of sacituzumab govitecan + pembrolizumab in TNBC, recently approved based on the ASCENT04/KEYNOTED19 trial. And the concept of T-cell "stemless" is intriguing with possibilities: DOI: 10.1056/NEJMcibr2601002 Learning Oncology Companion:… [Listen](https://feeds.soundcloud.com/stream/2346846131-user-650920398-breast-cancer-updates-and-t.mp3) ## [Updates on capivasertib, belzutifan, talquetamab, & durvalumab](https://soundcloud.com/user-650920398/updates-on-capivasertib) _2026-06-18 · OncoPharm_ Lots of bite-size updates in this episode. Capitello-281: capivasertib + abiraterone (+ prednisone + ADT) Adjuvant Belzutifan + Pemroblizumab is FDA approved Durvalumab approved with BCG for non-muscle invasive bladder cancer Insightful commentary: https://doi.org/10.1200/JCO-25-02670 Talquetamab + Durvaluamb - a new safety signal? Learning Oncology Companion:… [Listen](https://feeds.soundcloud.com/stream/2342058656-user-650920398-updates-on-capivasertib.mp3) ## [MPR Weekly Dose Podcast #278 — Once-Weekly HIV Tx; Hympavzi Approval Expanded; Orforglipron Assessed in Menopause; Warning Label for Weight Loss Tx](https://mprweeklydose.libsyn.com/mpr-weekly-dose-podcast-278-once-weekly-hiv-tx-hympavzi-approval-expanded-orforglipron-assessed-in-menopause-warning-label-for-weight-loss-tx) _2026-06-12 · MPR Weekly Dose_ A single, once-weekly tablet could change HIV treatment landscape; weight loss drug orforglipron efficacy assessed at all stages of menopause; hemophilia treatment Hympavzi gains expanded indication; and the FDA adds a warning label for kidney injury to an over-the-counter weight loss aid. [Listen](https://traffic.libsyn.com/secure/mprweeklydose/MPR_Weekly_Dose_Podcast_278__Once-Weekly_HIV_Tx_Orforglipron_Assessed_in_Menopause_Hympavzi_Approval_Expanded_Warning_Label_for_Weight_Loss_Tx_mixdown.mp3?dest-id=1953617) ## [ASCO '26](https://soundcloud.com/user-650920398/asco-26) _2026-06-11 · OncoPharm_ ASCO 2026 is a wrap, and we needed an extra week to digest it all! Here the review list: 1. RASolute 302 - daraxonrasib and its standing ovation 2. MajesTEC-9 - 2L teclistamab in multiple myeloma in patient population 100% exposed to CD-38 targeting drugs 3. Initsmeran autogene + pembrolizumab in resected melanoma. Only a Phase 2 study, but super promising and exciting use of personalized medicine… [Listen](https://feeds.soundcloud.com/stream/2337006764-user-650920398-asco-26.mp3) ## [MPR Weekly Dose Podcast #277 — Treatment Approved for cUTI; COVID-19 Postexposure Prophylaxis; Eye Drops Fail to Meet Endpoint; Afrezza Indication Expanded; Obefazimod UC Trial Results](https://mprweeklydose.libsyn.com/mpr-weekly-dose-podcast-277-treatment-approved-for-cuti-covid-19-postexposure-prophylaxis-eye-drops-fail-to-meet-endpoint-afrezza-indication-expanded-obefazimod-uc-trial-results) _2026-06-05 · MPR Weekly Dose_ New treatment approved for adults with complicated urinary tract infections; Xocova approved for COVID-19 postexposure prophylaxis; investigational diabetic macular edema eye drop fails to meet trial endpoint; Afrezza expanded for pediatric use; obefazimod looks promising for ulcerative colitis. [Listen](https://traffic.libsyn.com/secure/mprweeklydose/MPR_Weekly_Dose_Podcast_277__Treatment_Approved_for_cUTI_COVID-19_Postexposure_Prophylaxis_Tx_Eye_Drops_Fail_to_Meet_Endpoint_Afrezza_Indication_Expanded_Obefazimod_UC_Trial_Results.mp3?dest-id=1953617) ## [MPR Daily Dose Podcast #276 — Retatrutide Shows Significant Weight Loss; Hepcludex Approved; Acne Gel for OTC Use; Linzess Indication Expanded; Camizestrant Review Extended](https://mprweeklydose.libsyn.com/mpr-daily-dose-podcast-276-retatrutide-shows-significant-weight-loss-hepcludex-approved-acne-gel-for-otc-use-linzess-indication-expanded-camizestrant-review-extended) _2026-05-29 · MPR Weekly Dose_ New triple hormone receptor agonist shows significant weight loss; hepatitis delta virus treatment gains accelerated approval; acne gel gains OTC designation; constipation treatment expanded to include younger patients; and the FDA extends review for camizestrant in advanced breast cancer. [Listen](https://traffic.libsyn.com/secure/mprweeklydose/MPR_Daily_Dose_Podcast_276__Retatrutide_Shows_Significant_Weight_Loss_Hepcludex_Approved_Acne_Gel_for_OTC_Use_Linzess_Indication_Expanded_Camizestrant_Review_Extended_mixdown.mp3?dest-id=1953617) ## [AI QA That Opens Fix PRs (Sponsored)](https://crawlproof.com/a/ehZViuPuvrh0) _2026-05-29 · **Sponsored**_ Runs browser QA, files issues with repro evidence, and opens fix PRs. ## [MPR Daily Dose #275 — Top OTC Meds and Products; FDA Assess Safety in Pregnancy; Efgartigimod gMG Indication Broadened; R/R Mantle Cell Lymphoma Approval; ALS Treatment Fast Tracked](https://mprweeklydose.libsyn.com/mpr-daily-dose-275-top-otc-meds-and-products-fda-assess-safety-in-pregnancy-efgartigimod-gmg-indication-broadened-rr-mantle-cell-lymphoma-approval-als-treatment-fast-tracked) _2026-05-15 · MPR Weekly Dose_ US News and World Report releases their annual best over-the-counter products list; new guidance for drug safety evaluation during pregnancy; gMG indication broadened for efgartigimod; Beqalzi gains accelerated approval for MCL; and a novel treatment fast tracked for ALS. [Listen](https://traffic.libsyn.com/secure/mprweeklydose/MPR_Daily_Dose_275__Top_OTC_Meds_and_Products_FDA_Framework_to_Assess_Safety_in_Pregnancy_Efgartigimod_gMG_Indication_Broadened_RR_Mantle_Cell_Lymphoma_Approval_ALS_Treatment_Fast_Tracked_mixdown.mp3?dest-id=1953617)